Who has been buying Onco Cross stock?

1 distinct insiders have filed 0 disclosed insider purchases in Onco Cross (382150), most recently on 2026-04-21. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Onco Cross have?

Onco Cross has 0 buy-side and 8 sell-side disclosures on record, covering ₩3.4B ($2.3M) in total reported value, spanning 2024-12-18 to 2026-04-21.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Onco Cross 382150

Company

온코크로스Onco Cross

Insiders

Buys

Total Value

₩3.4B ($2.3M)

Avg Return

+49.78%

Last Filing

2026-04-21

Onco Cross (382150) has 0 disclosed insider purchases and 8 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩3.4B ($2.3M) in reported transaction value. The earliest filing StockDrifts holds for Onco Cross is dated 2024-12-18; the most recent is 2026-04-21. Across these filings the average return since disclosure is +49.78%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-04-21	SELL	증여	강지훈 Jihoon Kang	Each CEO	-30.0K	₩8,820	-2.5%	₩265M ($184K)
2026-02-27	BUY	주식매수청구권 행사	강지훈 Jihoon Kang	Each CEO	48.0K	-	-	-
2026-02-23	SELL	증여	채희진 Chae Hee-jin	Internal director	-18.0K	-	-	-
2026-02-09	SELL	주식매수청구권 행사	강지훈 Jihoon Kang	Each CEO	-36.0K	₩8,160	+4.0%	₩294M ($204K)
2026-02-09	SELL	주식매수청구권 행사	강지훈 Jihoon Kang	Each CEO	-12.0K	₩8,160	+4.0%	₩98M ($68K)
2026-01-12	BUY	주식매수선택권	채희진 Chae Hee-jin	Internal director	18.0K	₩9,440	-17.1%	₩170M ($118K)
2025-04-18	SELL	Market Sell	인터베스트 Intervest	-	-2.7K	₩15,590	+49.8%	₩42M ($29K)
2025-04-18	SELL	Market Sell	인터베스트 Intervest	-	-573	₩15,590	+49.8%	₩9M ($6K)
2025-04-18	SELL	Market Sell	인터베스트 Intervest	-	-161.1K	₩15,590	+49.8%	₩2.5B ($1.7M)
2025-04-18	SELL	Market Sell	인터베스트 Intervest	-	-283	₩15,590	+49.8%	₩4M ($3K)
2025-04-18	SELL	Market Sell	인터베스트 Intervest	-	-292	₩15,590	+49.8%	₩5M ($3K)
2025-04-18	SELL	Market Sell	인터베스트 Intervest	-	-10.3K	₩15,590	+49.8%	₩161M ($112K)
2025-04-18	SELL	Market Sell	인터베스트 Intervest	-	-20.2K	₩15,590	+49.8%	₩315M ($219K)
2025-04-18	SELL	Market Sell	인터베스트 Intervest	-	-20.6K	₩15,590	+49.8%	₩321M ($223K)
2025-03-28	BUY	주식매수선택권	강지훈 Jihoon Kang	vice president	300.0K	₩10,600	-26.1%	₩3.2B ($2.2M)
2024-12-18	BUY	신규상장	인터베스트 Intervest	-	1.2M	₩8,960	-12.6%	₩10.8B ($7.5M)
2024-12-18	BUY	신규상장	강지훈 Jihoon Kang	vice president	20.8K	₩8,960	-12.6%	₩186M ($129K)
2024-12-18	BUY	신규상장	강지훈 Jihoon Kang	vice president	60.0K	₩8,960	-12.6%	₩538M ($373K)
2024-12-18	BUY	신규상장	김이랑 With Kim	CEO	2.1M	₩8,960	-12.6%	₩18.4B ($12.8M)

Frequently asked questions

Who has been buying Onco Cross stock?: 1 distinct insiders have filed 0 disclosed insider purchases in Onco Cross (382150), most recently on 2026-04-21. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Onco Cross have?: Onco Cross has 0 buy-side and 8 sell-side disclosures on record, covering ₩3.4B ($2.3M) in total reported value, spanning 2024-12-18 to 2026-04-21.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.